

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3704237

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS VACCINE AND DIAGNOSTICS INC.	12/08/2015
RECEIVING PARTY DATA	
Name:	GlaxoSmithKline Biologicals SA
Street Address:	rue de l'Institut 89
City:	Rixensart
State/Country:	BELGIUM
Postal Code:	B-1330
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8178086
CORRESPONDENCE DATA	
Fax Number:	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	610-270-6812
Email:	US_CIPKOP@GSK.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	CIP UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	VN52029
NAME OF SUBMITTER:	ARLENE E CANNON
SIGNATURE:	/Arlene E Cannon/
DATE SIGNED:	01/20/2016
Total Attachments: 1	
source=VN52029 US confirmatory assignment#page1.tif	

CONFIRMATORY ASSIGNMENT

WE, **NOVARTIS VACCINES AND DIAGNOSTICS, INC.** a company incorporated under the State of Delaware, United States of America (registration number 2108457) and whose registered office is 2711 Centerville Road, Suite 400, Wilmington Delaware 19808 United States of America do hereby declare that we are the sole owner of the following patent(s)/patent application(s):

Canada Application Number 2636032 filed 4 January 2007 entitled Activation of HCV-Specific T Cells

United States Patent 8178086 granted 11 February 2010 entitled HCV-Specific T Cells

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS VACCINES AND DIAGNOSTICS, INC.** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS VACCINES AND DIAGNOSTICS, INC.** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium


Dated this 8 day of December 2015.

Signed for and on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS, INC.



Helen Lee
Authorized Attorney on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA



Lorraine B. Ling
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA